アッセイID: U017 | 報告日: 2011/03/02 | 所属: 三重大学医学部 | アッセイ者名: 広川佳史 | アッセイ名: RhoB過剰発現細胞の運動能に与える影響 |
概要 前立腺がんDU145細胞にRhoBを過剰発現させると細胞の運動能が亢進する。運動能亢進を抑制する阻害剤を同定し、RhoBとの関連を調べるのが目的。細胞をDilにて蛍光標識し、Boyden chamberの底部に阻害剤を入れる。一晩培養し、chamberの裏側に移動した細胞をプレートリーダーで測定する。GSK-3 inhibitorの3種、GSK-3 inhibitor IX ,1-Azakenpaullone, Indirubin-3'-monoxime-5-sulphonic Acidが細胞移動を抑制した。 |
||||
評価のクライテリア プレートリーダーによる蛍光測定値が103以下 |
||||
発表論文 | レポート提出者によるレポート内容の最終確認日: - |
Well | KIT 1 | KIT 2 | KIT 3 | |||
compound | 結果 | compound | 結果 | compound | 結果 | |
1 - A | none (DMSO) | 150 | none (DMSO) | 177 | none (DMSO) | 151 |
1 - B | 5-FU | 141 | Pifithrin-a (cyclic) | 171 | ABT-702 | 217 |
1 - C | Bestatin Hydrochloride | 136 | PRIMA-1 | 133 | Akt Inhibitor IV | 137 |
1 - D | Bleomycin sulfate | 151 | Finasteride | 186 | Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 140 |
1 - E | Cisplatin | 156 | Aminoglutethimide | 172 | Akt Inhibitor XI | 194 |
1 - F | Methotrexate | 167 | Formestane | 156 | compound C | 155 |
1 - G | Mitomycin C | 132 | Mifepristone | 224 | ATM/ATR kinase inhibitor | 307 |
1 - H | Vinblastine sulfate | 162 | TOFA | 185 | ATM kinase inhibitor | 167 |
2 - A | Paclitaxel | 118 | Amastatin | 197 | Aurora kinase/cdk inhibitor | 108 |
2 - B | Flutamide | 128 | Actinonin | 213 | Aurora kinase inhibitor II | 163 |
2 - C | Daunorubicin, HCl | 165 | Oligomycin | 144 | Aurora kinase inhibitor III | 236 |
2 - D | Doxorubicin, HCl | 158 | Bafilomycin A1 | 107 | AG957 | 269 |
2 - E | Tamoxifen, citrate | 165 | HA 14-1 | 219 | LFM-A13 | 285 |
2 - F | Actinomycin D | 134 | BH3I-1 | 225 | Terreic acid | 293 |
2 - G | Camptothecin | 159 | LFM-A13 | 160 | KN-93 | 203 |
2 - H | Aclarubicin | 141 | Terreic acid | 191 | KN-62 | 365 |
3 - A | Etoposide (VP-16) | 152 | E-64d | 186 | Lavendustin C | 300 |
3 - B | Cytochalasin D | 124 | ALLN | 149 | Kenpaullone | 140 |
3 - C | 2',5'-dideoxyadenosine | 128 | CA-074 | 170 | purvalanol A | 129 |
3 - D | AKT inhibitor | 161 | Pepstatin A | 136 | Olomoucine | 433 |
3 - E | NL-71-101 | 133 | Z-GLF-CMK | 135 | Alsterpaullone, 2-cyanoethyl | 239 |
3 - F | AG957 | 141 | RS 102895 | 170 | Cdk1/2 inhibitor III | 201 |
3 - G | KN93 | 149 | SB 328437 | 145 | Cdk2/9 inhibitor | 155 |
3 - H | Z-VAD-FMK | 137 | SB 225002 | 81 | NU6102 | 145 |
4 - A | Kenpaullone | 92 | AMD3100 octahydrochloride | 186 | Cdk4 inhibitor | 226 |
4 - B | Purvalanol A | 113 | NSC95397 | 203 | NSC625987 | 271 |
4 - C | 3-ATA | 122 | SC-ααδ9 | 148 | SB218078 | 173 |
4 - D | Olomoucine | 133 | Amiloride | 165 | isogranulatimide | 217 |
4 - E | TBB | 137 | Lidocaine | 190 | Chk2 inhibitor | 146 |
4 - F | Sulindac sulfide | 123 | Monensin | 108 | Chk2 inhibitor II | 150 |
4 - G | Valeryl salicylate | 137 | Ouabain | 82 | Ellagic acid (Dihydrate) | 243 |
4 - H | NS-398 | 127 | Sanguinarine | 66 | TBB | 239 |
5 - A | Sodium salicylate | 143 | Glibenclamide | 169 | DMAT | 373 |
5 - B | Theophylline | 127 | Dequalinium | 116 | D4476 | 248 |
5 - C | Azacytidine | 127 | Diazoxide | 147 | TG003 | 234 |
5 - D | Aphidicolin | 148 | Valinomycin | 93 | Diacylglycerol kinase inhibitor II | 239 |
5 - E | AG1478 | 152 | Nigericin | 131 | IC60211 | 248 |
5 - F | Genistein | 123 | Diltiazem | 236 | TX-1918 | 277 |
5 - G | Manumycin A | 161 | Nifedipine | 178 | BPIQ-Ⅱ | 194 |
5 - H | FTI-276 | 176 | Verapamil | 170 | AG1478 | 224 |
6 - A | SU1498 | 150 | PGP-4008 | 132 | AG490 | 295 |
6 - B | GGTI-286 | 171 | Fumitremorgin C | 144 | SU4984 | |
6 - C | Dexamethasone | 150 | A23187 | 111 | SU5402 | 211 |
6 - D | GSK-3 inhibitor II | 164 | Ionomycin | 99 | Flt-3 Inhibitor | 193 |
6 - E | Scriptaid | 145 | Thapsigargin | 87 | cFMS Receptor Tyrosine Kinase Inhibitor | 267 |
6 - F | Trichostatin A | 143 | t-Butylhydroquinone (BHQ) | 138 | SU6656 | 238 |
6 - G | AG825 | 177 | N-phenylanthranilic acid | 182 | GSK-3 inhibitor IX | 103 |
6 - H | Cycloheximide | 153 | DIDS | 106 | 1-Azakenpaullone | 105 |
7 - A | Lovastatin | 201 | SB 218078 | 169 | Indirubin-3'-monoxime | 46 |
7 - B | Radicicol | 125 | Debromohymenialdisine (DBH) | 167 | AG825 | 134 |
7 - C | 17-AAG | 114 | Rotenone | 119 | AG1024 | 209 |
7 - D | AG1024 | 194 | Antimycin A1 | 94 | AGL 2263 | 155 |
7 - E | 1400W, HCl | 172 | Leptomycin B* | 162 | BMS-345541 | 428 |
7 - F | AMT, HCl | 166 | R59022 | 166 | IKK-2 inhibitor VI | 123 |
7 - G | AG490 | 164 | Dioctanoylglycol | 151 | IRAK-1/4 inhibitor | 314 |
7 - H | Cucurbitacin I | 155 | RHC80267 | 130 | JAK Inhibitor I | 244 |
8 - A | SP600125 | 140 | Xanthohumol | 110 | JAK3 Inhibitor VI | 120 |
8 - B | Damnacanthal | 152 | C75 | 169 | SP600125 | 223 |
8 - C | PD 98059 | 172 | Cerulenin | 122 | JNK inhibitor VIII | 269 |
8 - D | U0126 | 149 | Tunicamycin | 85 | Damnacanthal | 155 |
8 - E | Fumagillin | 182 | Deoxynojirimycin | 188 | PP2 | 119 |
8 - F | GM 6001 | 168 | Swainsonine | 185 | ERK inhibitor II | 235 |
8 - G | N-Acetyl-L-cysteine | 181 | LY 83583 | 113 | PD98059 | 209 |
8 - H | Aminoguanidine, HCl | 195 | ODQ | 229 | U-0126 | 110 |
9 - A | L-NMMA | 165 | Anacardic acid | 126 | MEK inhibitor I | 178 |
9 - B | PD169316 | 136 | Chetomin | 66 | SU11274 | 130 |
9 - C | SB 203580 | 176 | Dimethyloxalylglycine | 192 | ML-7 | 189 |
9 - D | Rapamycin | 178 | HR22C16 | 104 | SB202190 | 87 |
9 - E | NU1025 | 185 | Monastrol | 150 | SB239063 | 145 |
9 - F | Benzamide | 168 | Nordihydroguaiaretic acid (NDGA) | 130 | AG1296 | 132 |
9 - G | D609 | 164 | ETYA | 192 | SU11652 | 90 |
9 - H | IBMX | 165 | Baicalein | 147 | PDGF receptor tyrosine kinase inhibitor V | 97 |
10 - A | Ro-20-1724 | 159 | Nutlin-3 | 179 | PDGF receptor tyrosine kinase inhibitor IV | 102 |
10 - B | Zaprinast | 170 | MDM2 inhibitor | 179 | LY-294002 | 162 |
10 - C | AG1296 | 170 | Phenelzine | 166 | Wortmannin | 78 |
10 - D | LY294002 | 168 | Deprenyl | 182 | H-89 | 464 |
10 - E | Wortmannin | 148 | Decylubiquinone | 189 | 4-cyano-3-methylisoquinoline | 243 |
10 - F | H-89, HCl | 160 | Ro 5-4864 | 264 | Bisindolymaleimide I, HCl | 92 |
10 - G | Bisindolymaleimide I, HCl | 128 | Lonidamine | 210 | Go7874 | 134 |
10 - H | H-7 | 166 | ML-7 | 137 | Rp-8-CPT-cGMPS | 376 |
11 - A | Staurosporine | 135 | Benzylguanine | 211 | KT5823 | 244 |
11 - B | cPLA2inhibitor | 144 | DFMO | 203 | PKR inhibitor | 67 |
11 - C | OBAA | 141 | KT 5823 | 176 | RAF1 kinase inhibitor I | 244 |
11 - D | Cantharidin | 169 | Rp-8-CPT-cGMPS | 269 | ZM 336372 | 239 |
11 - E | Cytostatin | 185 | MK 886 | 184 | H-1152 | 269 |
11 - F | Cyclosporin A | 149 | Clofibrate | 230 | Y-27632 | 303 |
11 - G | FK-506 | 155 | BADGE | 167 | radicicol | 95 |
11 - H | MG-132 | 157 | Troglitazone | 170 | PP1 analog | 167 |
12 - A | Lactacystin | 144 | AZT | 337 | Syk inhibitor | 169 |
12 - B | Hydroxyurea | 150 | Nalidixic acid | 174 | SB431542 | 190 |
12 - C | HA1077 | 137 | a-Amanitin | 66 | TGF-b RI kinase inhibitor II | 267 |
12 - D | Y27632 | 143 | MST-312 | 207 | Tpl2 kinase inhibitor | 203 |
12 - E | PP1 (analog) | 165 | b-Rubromycin | 111 | TrkA inhibitor | 123 |
12 - F | PP-H | 146 | SB 431542 | 170 | VEGFR receptor tyrosine kinase inhibitor II | 167 |
12 - G | Nocodazole | 143 | N1,N12-Diethylspermine (BESpm) | 126 | VEGF recptor 2 kinase inhibitor I | 254 |
12 - H | Dephostatin | 155 | Fumonisin B1 | 268 | SU1498 | 193 |